Trials / Completed
CompletedNCT00431496
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)
A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to show that the use of cinacalcet in patients with End Stage Renal Disease can help achieve NKF K/DOQI targets for both serum calcium and calcium phosphorous product.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cinacalcet | Cinacalcet tablets |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2009-06-01
- Completion
- 2009-10-01
- First posted
- 2007-02-05
- Last updated
- 2013-04-24
- Results posted
- 2011-07-13
Source: ClinicalTrials.gov record NCT00431496. Inclusion in this directory is not an endorsement.